Showing 13 to 24 of 68 results
Weight Regain Follows GLP-1 Medication Discontinuation
A study in BMC Medicine reveals that patients stopping GLP-1 weight-loss drugs like Wegovy and Ozempic regain weight within two months, highlighting the chronic nature of obesity and need for ongoing management, despite continued healthy habits.
Weight Regain Follows GLP-1 Medication Discontinuation
A study in BMC Medicine reveals that patients stopping GLP-1 weight-loss drugs like Wegovy and Ozempic regain weight within two months, highlighting the chronic nature of obesity and need for ongoing management, despite continued healthy habits.
Progress
36% Bias Score
High Costs, Inconsistent Coverage Limit Access to Popular Obesity Drugs
High prices and inconsistent insurance coverage limit access to the popular obesity medications Wegovy and Ozempic, despite falling costs and some employer-sponsored plans expanding coverage; the medications cost around $500 per month without insurance, forcing doctors to find creative solutions and...
High Costs, Inconsistent Coverage Limit Access to Popular Obesity Drugs
High prices and inconsistent insurance coverage limit access to the popular obesity medications Wegovy and Ozempic, despite falling costs and some employer-sponsored plans expanding coverage; the medications cost around $500 per month without insurance, forcing doctors to find creative solutions and...
Progress
40% Bias Score
Spain Investigates Novo Nordisk for Potentially Illegal Weight-Loss Drug Advertising
Spain is investigating Novo Nordisk for potentially illegal advertising of its weight-loss drugs Ozempic and Wegovy, following similar accusations in Ireland and the UK, prompting concerns about pharmaceutical marketing tactics and their impact on national health budgets.
Spain Investigates Novo Nordisk for Potentially Illegal Weight-Loss Drug Advertising
Spain is investigating Novo Nordisk for potentially illegal advertising of its weight-loss drugs Ozempic and Wegovy, following similar accusations in Ireland and the UK, prompting concerns about pharmaceutical marketing tactics and their impact on national health budgets.
Progress
48% Bias Score
US GLP-1 Drug Affordability Crisis
High costs and limited insurance coverage of GLP-1 weight-loss drugs like Ozempic and Wegovy are creating an affordability crisis in the US, with millions losing coverage in 2025; potential solutions include allowing compounding pharmacies to produce personalized prescriptions and revoking patent ex...
US GLP-1 Drug Affordability Crisis
High costs and limited insurance coverage of GLP-1 weight-loss drugs like Ozempic and Wegovy are creating an affordability crisis in the US, with millions losing coverage in 2025; potential solutions include allowing compounding pharmacies to produce personalized prescriptions and revoking patent ex...
Progress
52% Bias Score
GLP-1 RA Drugs May Double Macular Degeneration Risk in Diabetic Patients
A Canadian study of over 1 million Ontario residents with diabetes revealed that GLP-1 RA drugs, such as semaglutide and lixisenatide, may at least double the risk of developing neovascular age-related macular degeneration after six months of use, particularly in older patients or those with a histo...
GLP-1 RA Drugs May Double Macular Degeneration Risk in Diabetic Patients
A Canadian study of over 1 million Ontario residents with diabetes revealed that GLP-1 RA drugs, such as semaglutide and lixisenatide, may at least double the risk of developing neovascular age-related macular degeneration after six months of use, particularly in older patients or those with a histo...
Progress
48% Bias Score
Wegovy Use Among Teens Increases by 50% in 2024
Data shows a 50% increase in Wegovy prescriptions for American teens in 2024, reaching 14.8 per 100,000 adolescents, despite concerns about long-term effects and limited insurance coverage; this follows a strong recommendation from the American Academy of Pediatrics in January 2023.
Wegovy Use Among Teens Increases by 50% in 2024
Data shows a 50% increase in Wegovy prescriptions for American teens in 2024, reaching 14.8 per 100,000 adolescents, despite concerns about long-term effects and limited insurance coverage; this follows a strong recommendation from the American Academy of Pediatrics in January 2023.
Progress
36% Bias Score
GLP-1 Agonists Show Significant Dementia Risk Reduction
A large Irish study of 164,531 participants found that GLP-1 agonists, like Ozempic and Wegovy, reduced dementia risk by 45 percent, potentially offering a preventative measure for both diabetes and dementia, conditions on the rise in the US.
GLP-1 Agonists Show Significant Dementia Risk Reduction
A large Irish study of 164,531 participants found that GLP-1 agonists, like Ozempic and Wegovy, reduced dementia risk by 45 percent, potentially offering a preventative measure for both diabetes and dementia, conditions on the rise in the US.
Progress
44% Bias Score
MHRA Investigates Link Between GLP-1 Drugs and Pancreatitis
The UK's MHRA is investigating a possible link between GLP-1 weight-loss drugs and pancreatitis, prompting a review of 560 cases, although current data doesn't indicate rates exceeding those in clinical trials; experts warn against unregulated use.
MHRA Investigates Link Between GLP-1 Drugs and Pancreatitis
The UK's MHRA is investigating a possible link between GLP-1 weight-loss drugs and pancreatitis, prompting a review of 560 cases, although current data doesn't indicate rates exceeding those in clinical trials; experts warn against unregulated use.
Progress
44% Bias Score
UK Weight-Loss Injections Linked to Pancreatitis Cases
Over a million people in the UK have used weight loss and diabetes jabs, with the Medicines and Healthcare products Regulatory Agency (MHRA) reporting 294 cases of pancreatitis (inflammation of the pancreas) linked to these drugs, including five deaths. A new study will investigate genetic links.
UK Weight-Loss Injections Linked to Pancreatitis Cases
Over a million people in the UK have used weight loss and diabetes jabs, with the Medicines and Healthcare products Regulatory Agency (MHRA) reporting 294 cases of pancreatitis (inflammation of the pancreas) linked to these drugs, including five deaths. A new study will investigate genetic links.
Progress
48% Bias Score
Weight-Loss Injections Pose Contraceptive Risks: Urgent MHRA Warning
The UK's MHRA issued an urgent warning that weight-loss injections, including Ozempic, Wegovy, and Mounjaro, may reduce contraceptive effectiveness and pose risks to pregnant women and fetuses, prompting advice on birth control and immediate cessation upon pregnancy.
Weight-Loss Injections Pose Contraceptive Risks: Urgent MHRA Warning
The UK's MHRA issued an urgent warning that weight-loss injections, including Ozempic, Wegovy, and Mounjaro, may reduce contraceptive effectiveness and pose risks to pregnant women and fetuses, prompting advice on birth control and immediate cessation upon pregnancy.
Progress
60% Bias Score
MHRA Warns of Pregnancy Risk with Weight-Loss Drugs
The UK's MHRA issued a warning about 40 reported pregnancies in women using weight-loss drugs like Ozempic, Wegovy, and Mounjaro, advising them to use effective contraception due to potential interactions and lack of safety data during pregnancy.
MHRA Warns of Pregnancy Risk with Weight-Loss Drugs
The UK's MHRA issued a warning about 40 reported pregnancies in women using weight-loss drugs like Ozempic, Wegovy, and Mounjaro, advising them to use effective contraception due to potential interactions and lack of safety data during pregnancy.
Progress
52% Bias Score
Weight-Loss Drugs Linked to Increased Osteoporosis Risk
Weight-loss drugs such as Ozempic, Wegovy, and Mounjaro may cause significant bone and muscle loss, increasing osteoporosis risk, according to the Royal Osteoporosis Society. Up to 40 percent of weight loss from these drugs may come from bone and muscle, impacting approximately half a million users ...
Weight-Loss Drugs Linked to Increased Osteoporosis Risk
Weight-loss drugs such as Ozempic, Wegovy, and Mounjaro may cause significant bone and muscle loss, increasing osteoporosis risk, according to the Royal Osteoporosis Society. Up to 40 percent of weight loss from these drugs may come from bone and muscle, impacting approximately half a million users ...
Progress
56% Bias Score
Showing 13 to 24 of 68 results